Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:cabotegravir
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AX30
|
| gptkbp:chemicalFormula |
C19H17F2N3O5
|
| gptkbp:contraindication |
known hypersensitivity to cabotegravir
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:form |
extended-release injectable suspension
|
| gptkbp:frequency |
every 2 months after initial doses
|
| gptkbp:genericName |
gptkb:cabotegravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Apretude
|
| gptkbp:indication |
gptkb:pre-exposure_prophylaxis_(PrEP)
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:ViiV_Healthcare
|
| gptkbp:molecularWeight |
405.35 g/mol
|
| gptkbp:pregnancyCategory |
consult healthcare provider
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
fatigue headache muscle pain injection site reactions |
| gptkbp:storage |
refrigerate
|
| gptkbp:usedFor |
HIV prevention
|
| gptkbp:bfsParent |
gptkb:cabotegravir
|
| gptkbp:bfsLayer |
6
|